Plandai Biotechnology Overview
Get informed when a big investor buys or sells
+ Follow-87.33
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Plandai Biotechnology (PLPL) currently reports a P/E ratio of -87.33. That is below the Healthcare sector average of 70.94. Use the charts on this page to explore Plandai Biotechnology's P/E ratio history and peer comparisons.
Plandai Biotechnology's P/E ratio of -87.33 is lower than the Healthcare sector average of 70.94. That is roughly 223.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Plandai Biotechnology's market price to a fundamental measure such as earnings, sales, or book value. At -87.33, PLPL can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -87.33, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 70.94. From there, open related valuation or income-statement pages for Plandai Biotechnology, and consider following PLPL for alerts when major investors trade the stock.
Plandai Biotechnology is classified in the Healthcare sector. On P/E ratio, it currently shows -87.33 versus a sector average near 70.94. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PLPL with unrelated industries.
